I touched briefly on the Medimmune v. Genentech case in a previous Carnival of Biotechnology, but I didn’t go into […]

The latest Carnival of Biotechnology is up at Baby Biotechs. Great job, Brian! For more information, see the Carnival of

Just came across an article on diabetics going to Mexico to receive pig xenotransplants. Unlike other forms of medical tourism,

This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the

If there’s one sure rule about private equity, it is that there are no rules about private equity! Venture capitalists

Biotechnology companies have been facing a widening funding gap. Between frozen federal research budgets and a growing focus among venture

The United States is the world’s largest pharmaceutical market. Japan is the second largest, although the combined European Union is

Countries use various methods to control drug expenditures. Beyond simple negotiation, countries can also implement price controls or use WTO-authorized

Investing and Clinical Trials PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in

There’s been a lot of press floating around lately about the push to develop a framework for biogeneric (or biosimilar,